Scholarlink

<p>Acylation modification plays a crucial role in tumor progression through altering protein homeostasis and localization. However, a comprehensive summary of these processes is lacking. Protein acylation modifications are comprehensively summarized and categorized based on the amino acids that are modified. This review focuses on modifications of the lysine (acetylation, succinylation, crotonylation, malonylation, and glutarylation) and cysteine (myristoylation and palmitoylation) groups. The key enzymes involved in the occurrence and erasure of different modifications, as well as their effects on protein stability, cell localization, and tumor progression, are highlighted. The targeted delivery systems related to acylation modification are summarized, and currently available commercial inhibitors are also reviewed. Finally, acylation modifications with therapeutic potential in Phase I clinical trials are reviewed.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Processes and therapeutic perspectives of acylation modifications of lysine and cysteine in tumors

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年2月2日

查看全文
  • Jialin Jiang,
  • Jiabin Chen,
  • Shuhang Huang,
  • Yue Tian,
  • Lanyu Liu,
  • Jiahui Yao,
  • Yuzhu Zhang,
  • Can Jiang,
  • Xingting Zhang,
  • Na Han,
  • Guang Shu,
  • Gang Yin,
  • Li Xian Yip,
  • Kuoran Xing,
  • David Tai Leong,
  • Maonan Wang

摘要

Acylation modification plays a crucial role in tumor progression through altering protein homeostasis and localization. However, a comprehensive summary of these processes is lacking. Protein acylation modifications are comprehensively summarized and categorized based on the amino acids that are modified. This review focuses on modifications of the lysine (acetylation, succinylation, crotonylation, malonylation, and glutarylation) and cysteine (myristoylation and palmitoylation) groups. The key enzymes involved in the occurrence and erasure of different modifications, as well as their effects on protein stability, cell localization, and tumor progression, are highlighted. The targeted delivery systems related to acylation modification are summarized, and currently available commercial inhibitors are also reviewed. Finally, acylation modifications with therapeutic potential in Phase I clinical trials are reviewed.